181 related articles for article (PubMed ID: 24129246)
1. SILAC-based phosphoproteomics reveals an inhibitory role of KSR1 in p53 transcriptional activity via modulation of DBC1.
Zhang H; Xu Y; Filipovic A; Lit LC; Koo CY; Stebbing J; Giamas G
Br J Cancer; 2013 Nov; 109(10):2675-84. PubMed ID: 24129246
[TBL] [Abstract][Full Text] [Related]
2. Proteomic profile of KSR1-regulated signalling in response to genotoxic agents in breast cancer.
Zhang H; Angelopoulos N; Xu Y; Grothey A; Nunes J; Stebbing J; Giamas G
Breast Cancer Res Treat; 2015 Jun; 151(3):555-68. PubMed ID: 26022350
[TBL] [Abstract][Full Text] [Related]
3. Negative regulation of the deacetylase SIRT1 by DBC1.
Zhao W; Kruse JP; Tang Y; Jung SY; Qin J; Gu W
Nature; 2008 Jan; 451(7178):587-90. PubMed ID: 18235502
[TBL] [Abstract][Full Text] [Related]
4. Balance between SIRT1 and DBC1 expression is lost in breast cancer.
Sung JY; Kim R; Kim JE; Lee J
Cancer Sci; 2010 Jul; 101(7):1738-44. PubMed ID: 20412117
[TBL] [Abstract][Full Text] [Related]
5. Role of deleted in breast cancer 1 (DBC1) protein in SIRT1 deacetylase activation induced by protein kinase A and AMP-activated protein kinase.
Nin V; Escande C; Chini CC; Giri S; Camacho-Pereira J; Matalonga J; Lou Z; Chini EN
J Biol Chem; 2012 Jul; 287(28):23489-501. PubMed ID: 22553202
[TBL] [Abstract][Full Text] [Related]
6. Quantitative proteomics reveals that long non-coding RNA MALAT1 interacts with DBC1 to regulate p53 acetylation.
Chen R; Liu Y; Zhuang H; Yang B; Hei K; Xiao M; Hou C; Gao H; Zhang X; Jia C; Li L; Li Y; Zhang N
Nucleic Acids Res; 2017 Sep; 45(17):9947-9959. PubMed ID: 28973437
[TBL] [Abstract][Full Text] [Related]
7. Repression of estrogen receptor beta function by putative tumor suppressor DBC1.
Koyama S; Wada-Hiraike O; Nakagawa S; Tanikawa M; Hiraike H; Miyamoto Y; Sone K; Oda K; Fukuhara H; Nakagawa K; Kato S; Yano T; Taketani Y
Biochem Biophys Res Commun; 2010 Feb; 392(3):357-62. PubMed ID: 20074560
[TBL] [Abstract][Full Text] [Related]
8. Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma.
Lee H; Kim KR; Noh SJ; Park HS; Kwon KS; Park BH; Jung SH; Youn HJ; Lee BK; Chung MJ; Koh DH; Moon WS; Jang KY
Hum Pathol; 2011 Feb; 42(2):204-13. PubMed ID: 21056897
[TBL] [Abstract][Full Text] [Related]
9. Identification of DBC1 as a transcriptional repressor for BRCA1.
Hiraike H; Wada-Hiraike O; Nakagawa S; Koyama S; Miyamoto Y; Sone K; Tanikawa M; Tsuruga T; Nagasaka K; Matsumoto Y; Oda K; Shoji K; Fukuhara H; Saji S; Nakagawa K; Kato S; Yano T; Taketani Y
Br J Cancer; 2010 Mar; 102(6):1061-7. PubMed ID: 20160719
[TBL] [Abstract][Full Text] [Related]
10. DBC1 phosphorylation by ATM/ATR inhibits SIRT1 deacetylase in response to DNA damage.
Zannini L; Buscemi G; Kim JE; Fontanella E; Delia D
J Mol Cell Biol; 2012 Oct; 4(5):294-303. PubMed ID: 22735644
[TBL] [Abstract][Full Text] [Related]
11. Modification of DBC1 by SUMO2/3 is crucial for p53-mediated apoptosis in response to DNA damage.
Park JH; Lee SW; Yang SW; Yoo HM; Park JM; Seong MW; Ka SH; Oh KH; Jeon YJ; Chung CH
Nat Commun; 2014 Nov; 5():5483. PubMed ID: 25406032
[TBL] [Abstract][Full Text] [Related]
12. Chk2 and REGγ-dependent DBC1 regulation in DNA damage induced apoptosis.
Magni M; Ruscica V; Buscemi G; Kim JE; Nachimuthu BT; Fontanella E; Delia D; Zannini L
Nucleic Acids Res; 2014 Dec; 42(21):13150-60. PubMed ID: 25361978
[TBL] [Abstract][Full Text] [Related]
13. Acetylation status of P53 and the expression of DBC1, SIRT1, and androgen receptor are associated with survival in clear cell renal cell carcinoma patients.
Noh SJ; Kang MJ; Kim KM; Bae JS; Park HS; Moon WS; Chung MJ; Lee H; Lee DG; Jang KY
Pathology; 2013 Oct; 45(6):574-80. PubMed ID: 24018803
[TBL] [Abstract][Full Text] [Related]
14. MCC inhibits beta-catenin transcriptional activity by sequestering DBC1 in the cytoplasm.
Pangon L; Mladenova D; Watkins L; Van Kralingen C; Currey N; Al-Sohaily S; Lecine P; Borg JP; Kohonen-Corish MR
Int J Cancer; 2015 Jan; 136(1):55-64. PubMed ID: 24824780
[TBL] [Abstract][Full Text] [Related]
15. Deleted in breast cancer 1 (DBC1) deficiency results in apoptosis of breast cancer cells through impaired responses to UV-induced DNA damage.
Kim W; Kim JE
Cancer Lett; 2013 Jun; 333(2):180-6. PubMed ID: 23352644
[TBL] [Abstract][Full Text] [Related]
16. Carboxamide SIRT1 inhibitors block DBC1 binding via an acetylation-independent mechanism.
Hubbard BP; Loh C; Gomes AP; Li J; Lu Q; Doyle TL; Disch JS; Armour SM; Ellis JL; Vlasuk GP; Sinclair DA
Cell Cycle; 2013 Jul; 12(14):2233-40. PubMed ID: 23892437
[TBL] [Abstract][Full Text] [Related]
17. Deleted in breast cancer-1 regulates SIRT1 activity and contributes to high-fat diet-induced liver steatosis in mice.
Escande C; Chini CC; Nin V; Dykhouse KM; Novak CM; Levine J; van Deursen J; Gores GJ; Chen J; Lou Z; Chini EN
J Clin Invest; 2010 Feb; 120(2):545-58. PubMed ID: 20071779
[TBL] [Abstract][Full Text] [Related]
18. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma.
Cha EJ; Noh SJ; Kwon KS; Kim CY; Park BH; Park HS; Lee H; Chung MJ; Kang MJ; Lee DG; Moon WS; Jang KY
Clin Cancer Res; 2009 Jul; 15(13):4453-9. PubMed ID: 19509139
[TBL] [Abstract][Full Text] [Related]
19. SIRT7 promotes thyroid tumorigenesis through phosphorylation and activation of Akt and p70S6K1 via DBC1/SIRT1 axis.
Li H; Tian Z; Qu Y; Yang Q; Guan H; Shi B; Ji M; Hou P
Oncogene; 2019 Jan; 38(3):345-359. PubMed ID: 30093629
[TBL] [Abstract][Full Text] [Related]
20. A novel form of Deleted in breast cancer 1 (DBC1) lacking the N-terminal domain does not bind SIRT1 and is dynamically regulated in vivo.
Santos L; Colman L; Contreras P; Chini CC; Carlomagno A; Leyva A; Bresque M; Marmisolle I; Quijano C; Durán R; Irigoín F; Prieto-Echagüe V; Vendelbo MH; Sotelo-Silveira JR; Chini EN; Badano JL; Calliari AJ; Escande C
Sci Rep; 2019 Oct; 9(1):14381. PubMed ID: 31591441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
